Terms: = Bone cancer AND CCNE1, CCNE, 898, ENSG00000105173, P24864 AND Treatment
28 results:
1. [Mid-term analysis of prospective cohort study of rivaroxaban in preventing CRT in breast cancer].
Sang D; Fan SM; Li SY; Zhang JT; Wang HM; Zhao XH; Zheng LJ; Liang P; Xi GB; Zhao LM; Zhang YR; Yuan P
Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(3):256-262. PubMed ID: 38494772
[No Abstract] [Full Text] [Related]
2. Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the treatment of cancer.
Wang Y; Wang C; Liu T; Qi H; Chen S; Cai X; Zhang M; Aliper A; Ren F; Ding X; Zhavoronkov A
J Med Chem; 2024 Jan; 67(1):420-432. PubMed ID: 38146659
[TBL] [Abstract] [Full Text] [Related]
3. Tumor-suppressive microRNA-152 inhibits the proliferation of Ewing's sarcoma cells by targeting CDK5R1.
Kawano M; Tanaka K; Itonaga I; Iwasaki T; Kubota Y; Tsumura H
Sci Rep; 2023 Oct; 13(1):18546. PubMed ID: 37899376
[TBL] [Abstract] [Full Text] [Related]
4. Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma.
Kinnaman MD; Zaccaria S; Makohon-Moore A; Arnold B; Levine MF; Gundem G; Arango Ossa JE; Glodzik D; Rodríguez-Sánchez MI; Bouvier N; Li S; Stockfisch E; Dunigan M; Cobbs C; Bhanot UK; You D; Mullen K; Melchor JP; Ortiz MV; O'Donohue TJ; Slotkin EK; Wexler LH; Dela Cruz FS; Hameed MR; Glade Bender JL; Tap WD; Meyers PA; Papaemmanuil E; Kung AL; Iacobuzio-Donahue CA
Cancer Res; 2023 Nov; 83(22):3796-3812. PubMed ID: 37812025
[TBL] [Abstract] [Full Text] [Related]
5. The Targeted Therapies for Osteosarcoma
Wang S; Ren Q; Li G; Zhao X; Zhao X; Zhang Z
Curr Mol Pharmacol; 2024; 17(1):e210823220109. PubMed ID: 37602543
[TBL] [Abstract] [Full Text] [Related]
6. WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
Embaby A; Kutzera J; Geenen JJ; Pluim D; Hofland I; Sanders J; Lopez-Yurda M; Beijnen JH; Huitema ADR; Witteveen PO; Steeghs N; van Haaften G; van Vugt MATM; de Ridder J; Opdam FL
Gynecol Oncol; 2023 Jul; 174():239-246. PubMed ID: 37236033
[TBL] [Abstract] [Full Text] [Related]
7. Clinical Targeted Next-Generation Panel Sequencing Reveals
Marinoff AE; Spurr LF; Fong C; Li YY; Forrest SJ; Ward A; Doan D; Corson L; Mauguen A; Pinto N; Maese L; Colace S; Macy ME; Kim A; Sabnis AJ; Applebaum MA; Laetsch TW; Glade-Bender J; Weiser DA; Anderson M; Crompton BD; Meyers P; Zehir A; MacConaill L; Lindeman N; Nowak JA; Ladanyi M; Church AJ; Cherniack AD; Shukla N; Janeway KA
JCO Precis Oncol; 2023 Mar; 7():e2200334. PubMed ID: 36996377
[TBL] [Abstract] [Full Text] [Related]
8. Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges.
Hsu JY; Seligson ND; Hays JL; Miles WO; Chen JL
JCO Precis Oncol; 2022 Feb; 6():e2100211. PubMed ID: 35108033
[TBL] [Abstract] [Full Text] [Related]
9. Cross-cultural adaption, translation and validation of the Toronto extremity salvage score (TESS) for patients in German-speaking countries.
Trost C; Hofer C; Stamm T; Windhager R; Hobusch GM
Wien Klin Wochenschr; 2021 Jun; 133(11-12):536-542. PubMed ID: 33905027
[TBL] [Abstract] [Full Text] [Related]
10. Risk factors of distant metastasis after surgery among different breast cancer subtypes: a hospital-based study in Indonesia.
Anwar SL; Avanti WS; Nugroho AC; Choridah L; Dwianingsih EK; Harahap WA; Aryandono T; Wulaningsih W
World J Surg Oncol; 2020 May; 18(1):117. PubMed ID: 32473643
[TBL] [Abstract] [Full Text] [Related]
11. The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
Cell Death Dis; 2019 Apr; 10(4):324. PubMed ID: 30975979
[TBL] [Abstract] [Full Text] [Related]
12. MRI-based texture analysis of the primary tumor for pre-treatment prediction of bone metastases in prostate cancer.
Wang Y; Yu B; Zhong F; Guo Q; Li K; Hou Y; Lin N
Magn Reson Imaging; 2019 Jul; 60():76-84. PubMed ID: 30917943
[TBL] [Abstract] [Full Text] [Related]
13. Jaw bones regeneration using mesenchymal stem cells. A single-center experience.
Colangeli W; Riccelli U; Giudice A; Barca I; Caruso D; Novembre D; Tortosa C; Cordaro R; Cristofaro MG
Ann Ital Chir; 2018; 89():20-23. PubMed ID: 29629885
[TBL] [Abstract] [Full Text] [Related]
14. Intended Versus Inferred treatment After
Hillner BE; Hanna L; Makineni R; Duan F; Shields AF; Subramaniam RM; Gareen I; Siegel BA
J Nucl Med; 2018 Mar; 59(3):421-426. PubMed ID: 29191854
[TBL] [Abstract] [Full Text] [Related]
15. The clinicopathological spectrum of olfactory neuroblastoma and sinonasal neuroendocrine neoplasms: Refinements in diagnostic criteria and impact of multimodal treatments on survival.
Turri-Zanoni M; Maragliano R; Battaglia P; Giovannardi M; Antognoni P; Lombardi D; Morassi ML; Pasquini E; Tarchini P; Asioli S; Foschini MP; Sessa F; Nicolai P; Castelnuovo P; La Rosa S
Oral Oncol; 2017 Nov; 74():21-29. PubMed ID: 29103747
[TBL] [Abstract] [Full Text] [Related]
16. Multiparametric Magnetic Resonance Imaging of Prostate cancer bone Disease: Correlation With bone Biopsy Histological and Molecular Features.
Perez-Lopez R; Nava Rodrigues D; Figueiredo I; Mateo J; Collins DJ; Koh DM; de Bono JS; Tunariu N
Invest Radiol; 2018 Feb; 53(2):96-102. PubMed ID: 28906339
[TBL] [Abstract] [Full Text] [Related]
17. Combined diffusion-weighted imaging and dynamic contrast-enhanced MRI for differentiating radiologically indeterminate malignant from benign orbital masses.
Xu XQ; Qian W; Ma G; Hu H; Su GY; Liu H; Shi HB; Wu FY
Clin Radiol; 2017 Oct; 72(10):903.e9-903.e15. PubMed ID: 28501096
[TBL] [Abstract] [Full Text] [Related]
18. Utilization of palliative radiotherapy for bone metastases near end of life in a population-based cohort.
Tiwana MS; Barnes M; Kiraly A; Olson RA
BMC Palliat Care; 2016 Jan; 15():2. PubMed ID: 26748495
[TBL] [Abstract] [Full Text] [Related]
19. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract] [Full Text] [Related]
20. Clinical and pathological parameters prognostic for increased risk of recurrence after postoperative radiotherapy for temporal bone carcinoma.
Marioni G; Zanoletti E; Giacomelli L; Braggio L; Martini A; Mazzoni A
Head Neck; 2016 Jun; 38(6):894-8. PubMed ID: 26348213
[TBL] [Abstract] [Full Text] [Related]
[Next]
